Radiopharmaceutical Blockade: Manufacturing and Access Challenges in Australia

Australia is well positioned to become a global player in radiopharmaceuticals, especially theranostics that combine diagnosis and targeted therapy.

- 

Simone Leyden AM, Senior Director Global Public Affairs and Patient Advocacy, Telix Pharmaceuticals, Australia

However, critical policy gaps continue to hold the sector back. A convergence of factors has created this situation, including regulatory gaps, funding shortfalls and the rapid pace of industry innovation.

1. Fragmented Reimbursement Pathway

Unlike in the U.S., where agencies like the Centers for Medicare & Medicaid Services (CMS) offer clearer reimbursement protocols, Australia lacks a dedicated funding stream for radiopharmaceutical therapies. While diagnostics may be considered via the Medical Services Advisory Committee (MSAC), therapies fall outside both MSAC and the Pharmaceutical Benefits Advisory Committee (PBAC) remit, leading to funding uncertainty.

According to a Medicine's Australia report, Australia takes around 422 days on average to get cancer treatments funded, with some therapies taking up to seven years before reimbursement approval arrives—a process three to four times slower than in major markets such as the UK, Germany or Japan.

Medicines Australia's June 2025 policy position reiterated that there is no certainty in HTA pathways for radiopharmaceutical therapies, meaning companies face commercial ambiguity and patient access remains limited.

2. Sovereign Manufacturing Hampered by Policy Redundancies